Health ❯Healthcare ❯Patient Safety

Drug Side Effects

Brain Swelling Hospital Admissions Psychiatric Disorders Gastrointestinal Issues Post-Marketing Surveillance

Novo Nordisk's Amycretin Shows 22% Weight Loss in Trial, Boosting Stock

Growing Demand for Weight-Loss Drugs in the UK Raises Safety and Accessibility Concerns